GE HealthCare (GEHC) Stock Shrugs Off Q3 Earnings Beat And Raised Outlook

GE HealthCare Technologies stock barely flinched after its Q3 2026 release, edging about 1% higher to US$76.42. The market reaction looked calm. The headline was not. Management put up US$5.5b in revenue and a 16.6% adjusted EBIT margin, with free cash flow of US$793m, and then raised full year guidance.

If you trade on the next tick, that move might feel underwhelming. If you think in years, the story shifts to a business leaning on higher margins, a fatter backlog and a valuation that still prices in plenty of doubt.

Love GE HealthCare’s double digit EBIT margin and solid free cash flow but still wary about paying up when sentiment feels mixed? Compare it against a broader field of companies with strong balance sheets and fundamentals in our list of solid balance sheet and fundamentals stocks (22 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$5,513m vs. US$5,143m (+7.2%)
• Net Income (Q3 2026 vs. Q3 2025): US$615m vs. US$446m (+37.9%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$1.36 vs. US$0.98 (+38.9%)
• Adjusted EBIT Margin (Q3 2026 vs. Q3 2025): 16.6% vs. 14.8% (+180 bps)

GE HealthCare lifted guidance and is buying SOFIE Biosciences. Ask Charlie what SOFIE means for GE HealthCare’s margins.

Evaluating GE HealthCare’s Pipeline Milestones Against Q3 Proof

The bullish pitch hangs on GE HealthCare turning today’s pipeline into tomorrow’s higher margin engine.

"Rollout of Photonova Spectra photon counting CT, new 3T MR platforms and AI-powered imaging workflows is building a funnel of higher margin equipment and software that management expects to start contributing revenue meaningfully from the first half of 2027, which can support revenue growth and EBIT margin expansion."

Q3 shows early, concrete steps toward that goal rather than full payoff. CE Mark for Photonova Spectra, AI driven demand in Advanced Imaging Solutions and a 180 bps adjusted EBIT margin uplift all point to the mix tilting in the right direction. The US$23.7b backlog and 1.03x book to bill suggest that funnel is filling as planned.

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.

GE HealthCare Bear Case Runs Into Execution Check

Bears worry GE HealthCare’s AI and SaaS push drags on profitability before recurring software revenue matures.

"While healthcare providers are gradually adopting AI, cloud and enterprise imaging platforms, the integration of Intelerad and the shift to SaaS revenue will likely carry upfront integration and operating costs that weigh on adjusted EBIT margin before recurring software revenue becomes a larger share of total earnings."

This quarter shows the margin hit from that shift is not yet visible. Adjusted EBIT reached 16.6% with 180 bps expansion and EPS guidance moved up. Software momentum is present through CareIntellect and AI workflows, yet margin dilution from integration costs is not evident in these results.

Hunt Quiet Fundamentals Before They Move

GE HealthCare Technologies just reported a solid quarter alongside a muted share reaction. The real opportunity could sit in companies where fundamentals strengthen long before valuations catch up.

• Company 1 - 36% below our estimate - taps government backed trade in subsidies to pull more used devices into higher margin refurbishment.
• Company 2 - 43% below our estimate - converts a record backlog of data center heavy projects into long running installation and service revenue.
• Company 3 - 21% below our estimate - expands uptake of a surgical robotics platform that pulls more high acuity procedures into its ecosystem.

That is three of the list. See the full list of 30 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com